Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Prostatic Neoplasms 19Lung Neoplasms 14Multiple Myeloma 13Leukemia, Myeloid, Acute 12Glioma 10Wilms Tumor 9Lymphoma, Non-Hodgkin 9Breast Neoplasms 9Sarcoma 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Osteosarcoma 8Neuroblastoma 8Neoplasm Metastasis 8Myelodysplastic Syndromes 8Colorectal Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Carcinoma, Hepatocellular 8Rhabdoid Tumor 7Hepatoblastoma 7Rhabdomyosarcoma 6Pancreatic Neoplasms 6Ovarian Neoplasms 6Neuroectodermal Tumors, Primitive, Peripheral 6Medulloblastoma 6Lymphoma 6Histiocytosis, Langerhans-Cell 6Ependymoma 6Sarcoma, Ewing 5Rectal Neoplasms 5Melanoma 5

Interventions

enasidenib 1canakinumab 1X-Rays 1Specimen Handling 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Clonal Cytopenia of Undetermined Significance × X-Rays × 1 year × Clear all
NCT05641831 2026-01-02

Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
110 enrolled
Classical hematology

Clonal Cytopenia of Undetermined Significance

Data powered by HemOnc (CC BY 4.0) Colophon âš¡